• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.23% Nasdaq Up1.86%

    iCo Therapeutics Inc. (ICO.V)

    -TSXV
    0.04 0.00(0.00%) May 20
    ProfileGet Profile for:
    iCo Therapeutics Inc.


    Business Summary 

    iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008 (Bertilimumab), a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic indications; and Oral Amphotericin B Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections in immune-compromised patients, such as in HIV/AIDS, cancer, transplant recipients, diabetics, etc., as well as certain parasitical infections. iCo Therapeutics Inc. has partnership arrangements with Isis Pharmaceuticals, Inc.; MedImmune Limited; Immune Pharmaceuticals Inc.; AstraZeneca; and the University of British Columbia. iCo Therapeutics Inc. was founded in 2005 and is headquartered in Vancouver, Canada.

    Key Statistics